- Home
- REE vs TLSI Comparison
REE vs TLSI Comparison
Compare REE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- TLSI
- Stock Information
- Founded
- REE 2011
- TLSI 2010
- Country
- REE Israel
- TLSI United States
- Employees
- REE N/A
- TLSI N/A
- Industry
- REE Auto Manufacturing
- TLSI Medical Specialities
- Sector
- REE Consumer Discretionary
- TLSI Health Care
- Exchange
- REE Nasdaq
- TLSI Nasdaq
- Market Cap
- REE 153.8M
- TLSI 124.9M
- IPO Year
- REE N/A
- TLSI N/A
- Fundamental
- Price
- REE $7.25
- TLSI $4.53
- Analyst Decision
- REE Buy
- TLSI Strong Buy
- Analyst Count
- REE 4
- TLSI 5
- Target Price
- REE $9.25
- TLSI $12.10
- AVG Volume (30 Days)
- REE 50.2K
- TLSI 32.3K
- Earning Date
- REE 11-29-2024
- TLSI 11-14-2024
- Dividend Yield
- REE N/A
- TLSI N/A
- EPS Growth
- REE N/A
- TLSI N/A
- EPS
- REE N/A
- TLSI N/A
- Revenue
- REE $825,000.00
- TLSI $26,891,000.00
- Revenue This Year
- REE N/A
- TLSI $61.76
- Revenue Next Year
- REE $50,620.25
- TLSI $47.30
- P/E Ratio
- REE N/A
- TLSI N/A
- Revenue Growth
- REE N/A
- TLSI 67.92
- 52 Week Low
- REE $2.91
- TLSI $3.33
- 52 Week High
- REE $8.79
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- REE 50.95
- TLSI 58.12
- Support Level
- REE $6.16
- TLSI $3.74
- Resistance Level
- REE $8.79
- TLSI $4.66
- Average True Range (ATR)
- REE 0.62
- TLSI 0.37
- MACD
- REE -0.09
- TLSI 0.05
- Stochastic Oscillator
- REE 41.44
- TLSI 88.04
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.